Gilead avoids $1.2bn patent clash at SCOTUS

Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead defeats US govt in billion-dollar HIV drug patent suit

11 May 2023 Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

Big Pharma

Gilead defeats immunity bid in hepatitis C patent case

7 March 2023 The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.

Big Pharma

Trial set for Gilead HIV antitrust claims case

23 February 2023 Gilead, Johnson & Johnson and others will face trial in May | Class-action suit involves allegations of anticompetitive practices.